Investigating new compounds to protect brain cells in Parkinson's disease using zebrafish models
In vitro pharmacology and In vivo neuroprotective effects of CMPI analogues in an optimized Zebrafish model of Parkinsons disease
['FUNDING_OTHER'] · UNIVERSITY OF TEXAS TYLER · NIH-11082980
This study is looking for new medications that could help protect brain cells in people with Parkinson's disease by testing a special compound in zebrafish to see if it can keep important brain cells healthy and slow down the disease.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS TYLER (nih funded) |
| Locations | 1 site (TYLER, UNITED STATES) |
| Trial ID | NIH-11082980 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new drugs that can protect brain cells in patients with Parkinson's disease (PD). It aims to create and test analogs of a compound called CMPI, which may enhance the function of certain receptors in the brain that are important for neuroprotection and reducing inflammation. By using zebrafish models, the researchers will evaluate how effective these compounds are in preventing the loss of dopaminergic neurons, which are crucial for movement and coordination. The goal is to find treatments that not only alleviate symptoms but also modify the disease's progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease who are experiencing a decline in their motor functions.
Not a fit: Patients with Parkinson's disease who are in advanced stages and have significant neurodegeneration may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that slow down or even halt the progression of Parkinson's disease.
How similar studies have performed: Other research has shown promise in developing neuroprotective agents for Parkinson's disease, but this specific approach using CMPI analogs is relatively novel.
Where this research is happening
TYLER, UNITED STATES
- UNIVERSITY OF TEXAS TYLER — TYLER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HAMOUDA, AYMAN K. — UNIVERSITY OF TEXAS TYLER
- Study coordinator: HAMOUDA, AYMAN K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.